Zydus Lifesciences Secures USFDA Fast Track Designation for Usnoflast

Unknown Apr 02, 2026 750 Views

Zydus Lifesciences has received Fast Track Designation from the US Food and Drug Administration (USFDA) for Usnoflast (ZYIL1), a novel oral NLRP3 inflammasome inhibitor. The designation accelerates the development and review process, ensuring faster access for patients suffering from neuroinflamm...